Collegium Pharmaceutical Stock Price, News & Analysis (NASDAQ:COLL)

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

Collegium Pharmaceutical Inc (NASDAQ:COLL) released its earnings results on Wednesday, August, 7th. The specialty pharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.19) by $0.05. The specialty pharmaceutical company had revenue of $75.04 million for the quarter, compared to the consensus estimate of $75.77 million. Collegium Pharmaceutical had a negative net margin of 7.45% and a negative return on equity of 26.10%. Collegium Pharmaceutical's quarterly revenue was up 2.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.40) EPS. View Collegium Pharmaceutical's Earnings History.

Collegium Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Collegium Pharmaceutical.

6 analysts have issued 1-year price objectives for Collegium Pharmaceutical's stock. Their forecasts range from $22.00 to $33.00. On average, they anticipate Collegium Pharmaceutical's stock price to reach $26.20 in the next year. This suggests a possible upside of 127.4% from the stock's current price. View Analyst Price Targets for Collegium Pharmaceutical.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Collegium Pharmaceutical.

Media coverage about COLL stock has trended negative on Tuesday, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Collegium Pharmaceutical earned a coverage optimism score of -2.1 on InfoTrie's scale. They also gave media stories about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Collegium Pharmaceutical.

Collegium Pharmaceutical saw a decline in short interest in the month of September. As of September 15th, there was short interest totalling 2,810,000 shares, a decline of 7.0% from the August 15th total of 3,020,000 shares. Based on an average daily trading volume, of 275,600 shares, the short-interest ratio is presently 10.2 days. Approximately 10.1% of the company's stock are sold short. View Collegium Pharmaceutical's Current Options Chain.

Some companies that are related to Collegium Pharmaceutical include Alder Biopharmaceuticals (ALDR), Aimmune Therapeutics (AIMT), Corcept Therapeutics (CORT), Insmed (INSM), Heron Therapeutics (HRTX), Nabriva Therapeutics (NBRV), Supernus Pharmaceuticals (SUPN), Ironwood Pharmaceuticals (IRWD), Eidos Therapeutics (EIDX), Madrigal Pharmaceuticals (MDGL), Opko Health (OPK), Radius Health (RDUS), BELLUS Health (BLUSF), Enanta Pharmaceuticals (ENTA) and Zymeworks (ZYME).

Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include GALAPAGOS NV/S (GLPG), Celgene (CELG), NVIDIA (NVDA), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), Synergy Pharmaceuticals (SGYP), GW Pharmaceuticals PLC- (GWPH), Micron Technology (MU), Bausch Health Companies (BHC) and Advanced Micro Devices (AMD).

(COLL) raised $75 million in an initial public offering on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

Collegium Pharmaceutical's stock is owned by many different of retail and institutional investors. Top institutional investors include Strs Ohio (0.16%), Virginia Retirement Systems ET AL (0.13%), Campbell & CO Investment Adviser LLC (0.03%), Nisa Investment Advisors LLC (0.03%) and Meeder Asset Management Inc. (0.03%). Company insiders that own Collegium Pharmaceutical stock include Alison B Fleming, David Hirsch, Joseph Ciaffoni, Longitude Capital Partners, Ll, Michael Thomas Heffernan, Paul Brannelly and Scott Dreyer. View Institutional Ownership Trends for Collegium Pharmaceutical.

COLL stock was purchased by a variety of institutional investors in the last quarter, including Virginia Retirement Systems ET AL, Campbell & CO Investment Adviser LLC, Nisa Investment Advisors LLC, Meeder Asset Management Inc. and Strs Ohio. View Insider Buying and Selling for Collegium Pharmaceutical.

Shares of COLL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of COLL stock can currently be purchased for approximately $11.52.

Collegium Pharmaceutical has a market capitalization of $385.57 million and generates $280.41 million in revenue each year. The specialty pharmaceutical company earns $-39,130,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. Collegium Pharmaceutical employs 266 workers across the globe.View Additional Information About Collegium Pharmaceutical.

The official website for Collegium Pharmaceutical is http://www.collegiumpharma.com/.

Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The specialty pharmaceutical company can be reached via phone at 781-713-3699.